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Abstract 
Aims: Temporomandibular disorders (TMD) represent a heterogeneous group of inflammatory or 
degenerative diseases of the stomatognatic system, with algic and/or dysfunctional clinical features involving 
temporomandibular joint (TMJ) and related masticatory muscles. Rheumatoid Arthritis (RA) is an autoimmune 
polyarthritis characterized by the chronic inflammation of synovial joints and oral implications such as 
hyposalivation, difficulty in swallowing and phoning, feeling of burning mouth, increased thirst, loss of taste or 
unpleasant taste and smell, dental sensitivity. 
The aim of this observational study was to investigate the prevalence of TMD symptoms and signs as well as 
oral implications in patients with Early Rheumatoid Arthritis (ERA), that is a RA diagnosed within 12 months, 
compared with a control group.  
Methods: The study group included 52 ERA patients (11 men, 41 women) diagnosed according to the 2010 
ACR/EULAR Classification Criteria for Rheumatoid Arthritis. A randomly selected group of 52 patients not 
affected by this disease, matched by sex and age, served as the control group. The examination for TMD signs 
and symptoms was based on the standardized Research Diagnostic Criteria for Temporomandibular Disorders 
(RDC/TMD) by means of a questionnaire and through clinical examination. 
Results: Regarding the oral kinematics, the left lateral excursion of the mandible was restricted in statistically 
significant way in ERA patients (p=0.017). The endfeel values were significantly increased in ERA group 
(p=0.0017), thus showing the presence of a higher muscle contracture. On the other side, the study group 
complained less frequently (67.3%) of TDM symptoms (muscle pain on chewing, pain in the neck and shoulders 
muscles, difficulty in mouth opening, arthralgia of TMJ, tinnitus) than controls (90.4%) (χ2= 8.301 p=0.0039). 
The presence of TMJ noises was significantly lower in the study group (χ2= 3.869 p=0.0049), as well as presence 
of opening derangement (χ2= 14.014 p=0.0002).  
The salivary flow was significantly decreased in the study group respect to the control one (p<0.0001). 
Conclusions: The data collected show a weak TMJ kinematic impairment, a paucisymptomatic muscle 
contracture (positive endfeel) and a remarkable reduction of salivary flow in ERA patients. Myofacial pain (MP) 
evoked by palpation was more frequent and severe in the control group than in the study one, this result being 
highly significant. 
Key words: Early Rheumatoid Arthritis, temporomandibular disorders, RDC/TMD, oral implications. 
Introduction 
Rheumatoid arthritis (RA) is a systemic 
inflammatory polyarthritis, characterized by a 
predisposition for affecting and destroying the small 
joints of the hands and feet (although any synovial 
joint can be virtually affected) [1]. It also can involve 
several extra-articular organs. 
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The prevalence of RA is approximately 1% 
worldwide [2]. In industrialized countries, it affects 
0,5-2% of population, with an incidence of 12-200 
cases every 100.000 [3]. The incidence of new cases 
increases with age: the illness begins more commonly 
between 40 and 50 years (a little later in men) [4], but it 
can anyhow appear at any age. Regarding sex, RA 
affects women more frequently than men, in a ratio of 
2-4:1 [2]. Individuals affected have a high risk of 
incurring in disability and premature death, and they 
develop a probability of exitus twice higher than 
healthy individuals of the same age.  
RA is a chronic, stiffing and progressive disease, 
of unknown etiology, in which both genetic and 
environmental factors participate in mechanisms of 
pathogenesis [5]. The heritability of RA is estimated to 
be approximately 65% [6]. Genetic factors increase 
susceptibility to RA, such as the frequency of the 
serotypes of HLA-DR4, one of HLA class II genes [7]. 
Other serotypes, such as DR1, are also associated with 
an increased risk for RA, although to a lesser extent 
than DR4 [8]. However, also non-MHC genes are also 
associated with RA [9]. At 2014, 101 RA risk loci have 
been identified [10], including PADI4, PTPN22, 
TNFAIP3, TRAF1 / C5, REL, CCR6, FCRL3 
OLIG3/TNFAIP3, STAT4, TRAF1-C5, many of them 
involved in immune cell functions [8]. In addition to 
genetic factors, several environmental ones have been 
involved in the pathogenesis of RA, such as virus 
(Epstein-Barr, parvovirus B19), bacteria (Streptococcus, 
Mycoplasma, Proteus and E. coli), hormones, cigar and 
silica [11, 12]. 
Therefore, a high-risk genetic background, in 
combination with epigenetic marks and 
environmental exposures, leads to a cascade of events 
inducing synovitis [13], characterized by hyperplasia 
of the synovial lining (normally formed by two or 
three layers of synovial fibroblasts), that reaches a 
thickness of 10-15 cell layers (rheumatoid pannus), and 
invades and degrades the cartilage matrix and the 
subchondral bone, promoting joint destruction [14]. 
The anti-CCP antibodies (ACPAs), in addition to the 
proinflammatory cytokines, cause the local bone 
resorption [15]. Indeed, sera from the majority of RA 
patients contain autoantibodies like rheumatoid factor 
(RF) or anti-citrullinated protein antibodies (ACPAs). 
However, approximately 20% of RA are seronegative 
[8], so the values of ANA (antinuclear antibodies), 
CRP (C-reactive protein), ESR (erythrocyte 
sedimentation rate), Hb (hemoglobin), PLT (platelets) 
and WBC (white blood cells) must also be sought. The 
clinical diagnosis, far more important than the 
serological one, carries out through musculoskeletal 
objectivities and extraarticular manifestations. 
Furthermore, radiographs and several clinical 
imaging systems, such as magnetic resonance 
imaging (MRI), computed tomography (CT), 
ultrasonography (US), dual-energy X-ray 
absorptiometry (DXA) and digital X-ray 
radiogrammetry (DXR), are used to monitor bone 
changes in RA [16].  
The diagnosis performed through the ERA 
criteria within 12 months after the onset of clinical 
symptoms, is considered early [17].  
RA mainly affects the joints of the hands, wrists, 
elbows, shoulders, hips, knees, feet; less frequently, it 
involves other joints, such as the temporomandibular 
ones. From 4 up to 80% of RA patients (usually, more 
than 50% of them) clinically exhibit TMJ involvement 
[18]. The clinical findings in the TMJ affected by RA 
are pain, swelling, movement impairment and 
crepitation; moreover, in advanced stages, 
malocclusion of the teeth and anterior open bite may 
occur [19]. There is sensitivity or preauricular pain 
during joint movement, probably due to compression 
of retrodiscal tissue, stretching of the joint capsule and 
synovitis. There is also morning stiffness usually 
lasting more than 30 min and decreased masticatory 
force. In children, it may result in disturbance in 
mandibular growth, facial deformity and ankylosis, 
generally found in the later stages of the disease, but it 
is a rare finding [18]. The presence of morphologic 
alterations on conventional radiographs of the TMJ in 
RA patients varies from 19% to 86% [20]. The main 
changes are flattening, spiked deformity or pencil-like 
condylar head, cortical erosion, gradual decrease in 
joint space due to granulation, deossification, and sub 
cortical cysts [21, 22]. The use of the drugs can be 
associated with adverse events in the oral cavity, such 
as changes in mucous membranes and other 
symptoms different from patient to patient [23]. 
About half of the patients with RA (51.5%) complain 
xerostomia and, consequently, difficulties in 
swallowing and phonation, sensation of burning 
mouth, increased thirst, loss of taste, unpleasant taste 
and odor and dental sensitivity [24]. 
Nevertheless, the literature lacks studies about 
TMJ and masticatory muscles involvement in patients 
with ERA, so the relationship between this disease 
and the temporomandibular disorders is unclear [25]. 
Given this background, the aim of this study was to 
evaluate clinically, through signs and symptoms, the 
prevalence of temporomandibular disorders (TMD) 
and oral manifestations in a sample, homogeneous for 
ethnic origin, of ERA patients on drug therapy 
compared with a control group. If a significant 
correlation could be found, the complex relationship 
between this autoimmune disease and orofacial 
manifestations could be better understood. 
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The null hypothesis in this research was that 
ERA patients presented no differences in clinical 
characteristics and functional disabilities compared to 
a control group. 
Materials and Methods 
This clinical observational study was performed 
between June 2016 and February 2018 at the School of 
Dentistry and the Complex Operating Unit of 
Rheumatology, University of Bari, Italy, in accordance 
with the provisions of the Declaration of Helsinki. 
Ethical approval and informed consent from each 
human subject were obtained.  
Fifty-two patients (11 men, 41 women) of 
European origins with ERA, diagnosed according to 
ERA Criteria, were enrolled in the study group. A 
control group (CG) of 52 patients, matched by sex and 
age, was randomly selected among those presenting 
at the Dental Clinic for routine oral visit. The CG did 
not have any history of rheumatic disease.  
Exclusion criteria were previous facial trauma, 
head, oral or neck neoplasia, maxillofacial surgery. 
Patients age ranged between 8 and 86 years old, 
with a mean age of 55,96 (SD= 19,01) years in the ERA 
group, and 52,73 (SD=15,82) years in the controls. 
Patients’ drugs were recorded. The absolute level of 
disease activity was quantified through three indices: 
Disease activity score 28 (DAS28), Clinical Disease 
Activity Index (CDAI), and Simplified Disease 
Activity Index (SDAI). 
The TMD were assessed following the 
standardized Research Diagnostic Criteria for 
Temporomandibular Disorders (RDC/TMD) [26]. A 
single, skilled, nonblinded practitioner valued current 
symptoms and signs of both groups through an 
anamnestic questionnaire and clinical examination. 
Patient’s History 
Oral symptoms 
Through a questionnaire, patients recorded the 
presence/absence of the following diseases:  
a) Xerostomia: it is a complaint of dryness of oral 
cavity, due to a hyposalivation or to a complete lack of 
saliva [27]. It is classified as true xerostomia 
(xerostomia primaria), resulting from malfunction of 
the salivary glands, or pseudo xerostomia (xerostomia 
symptomatica), in the course of which the patient has 
a subjective impression of oral dryness despite a 
normal secretory function. Xerostomia affects mostly 
menopausal women and individuals above 65 years 
of age [28]. It is associated to discomfort in activities 
such as eating, speaking, swallowing and wearing 
dentures. 
b) Dysgeusia: it is an inability to discriminate all 
the basic tastes (total dysgeusia), often due to a zinc 
deficiency, or a limited number of basic tastes (partial 
dysgeusia) [29], due to an obstruction of selective taste 
receptors in taste cells, that can be induced by an 
autoimmune mechanism [30]. Dysgeusia was 
recorded when subjects experienced bitter, sour, or 
metallic flavors [31]. 
c) Stomatodynia: it is a condition often with an 
unclear etiopathogenesis, in which affected 
individuals complain of burning pain of the oral 
mucosa, especially on the tongue, accompanied by 
other sensory disorders such as xerostomia and 
dysgeusia [32]. 
TMD symptoms 
All complaints reported by patients were 
recorded through a questionnaire: (i) presence of pain 
in masticatory muscles (both at rest and during 
mandibular functions), (ii) pain or stiffening in the 
neck and shoulders muscles, (iii) difficulty in mouth 
opening, (iv) arthralgia of TMJ, (v) temporal 
headaches and tinnitus [33, 34, 35]. 
These data were collected as categorical ones 
(presence/absence of TMD). 
Clinical Examination 
Disease Activity 
To quantify the absolute level of disease activity 
of ERA patients, the mean values of three indices were 
used: (i) Clinical Disease Activity Index = CDAI), (ii) 
Simplified Disease Activity Index (SDAI) and (iii) 
Disease activity score in 28 joints (DAS28). 
Pharmacological Therapy 
ERA patients were asked about RA medication 
and about the beginning of treatment after diagnosis.  
Oral signs 
The following data were collected as categorical 
(presence/absence) of: 
• ulcers (aphthae) 
• erythema 
• candidiasis 
• angular cheilitis: is characterized by erythema, 
ulcerations, flaking of the labial and sting. The 
buccal opening is limited and painful.  
• hyperkeratotic or erythematous areas of the 
mucosa. 
• fissured tongue: presence of deep grooves on the 
tongue surface. 
• petechiae: small (< 3mm) red or purple spots, 
caused by a minor bleed from broken blood 
vessels. 
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Hyposalivation: is a result of several conditions, 
including dehydration, denervation, trauma, chronic 
immune and non-immune mediated inflammation of 
the salivary glands, head and neck irradiation 
therapy, psychologic factors and medications such as 
anticoagulants, antidepressants, antihypertensives, 
antiretrovirals, hypoglycemics, levothyroxine, 
multivitamins and supplements, non-steroidal 
anti-inflammatory drugs and steroid inhalers [36]. 
Hyposalivation is considered to appear when the 
unstimulated salivary flow (UWS) rate is < 
0.1 mL/min or the stimulated one (SWS) is < 
0.7 mL/min. [37]. 
In this study the test was conducted asking the 
patient to spit saliva, accumulated in the floor of the 
mouth without stimulation, in a graduated tube every 
60 seconds. The collection period lasted 5 minutes.  
Other oral characteristics analyzed were the 
integrity of the dental arches or presence of partial or 
total edentulism, the presence/absence of prostheses 
(mobile, fixed or both), and any previous or present 
orthodontic treatment.  
TMJ signs 
a) TMJ sounds (TMJs): they are perceived by 
placing the fingertips on the lateral surface of the 
condyle on each side separately, during the opening 
and closing movements of the mandible. 
Clicking is considered a net, sharp and 
short-lived noise. It can be single or reciprocal, early 
or late. 
Snapping sound is a “short duration” clicking, 
louder, sharper and with a higher pitch [38]. It’s also 
known as “pop noise”. Crepitation is a gravel-like 
noise, composed of a series of short duration sounds, 
occurring in rapid succession, [39], with a low pitch, 
also described as the gears of a cogwheel. 
b) Bruxism (BRUX): is defined by the American 
Academy of Sleep Medicine as the “repetitive jaw 
muscle activity, characterized by the clenching or 
grinding of teeth” [40]. There are two forms of 
bruxism: sleep bruxism (SB) or awake bruxism (AB), 
which are considered separate entities that differ in 
their etiology [41]. While AB is characterized mainly 
by the clenching of teeth [42], SB by the clenching and 
grinding [40]. Bruxism can cause myalgia (due to 
ischemia and an accumulation of metabolic 
biomarkers in the muscle tissue) [43], joint pain and 
oral signs, such as wear facets that alter the occlusal 
plane, irregular lingual edges and buccal occlusal line. 
c) Mandibular kinematics (MK) and restriction of 
movements (RM): 
i) Reduced opening: in a healthy masticatory 
system, the mouth opens between 53 and 58 mm. 
Taking into account overbite [44], an opening 
movement is considered restricted when the distance 
between the incisal edge of the maxillary and 
mandibular incisors is lower than 40mm. 
ii) Right and left lateral shifts: were recorded 
when the distance from upper to lower midline was < 
8mm. 
iii) Mandibular protrusion: the mean values 
range between 7 and 10 mm. It was recorded when < 
7mm [45]. 
iv) Endfeel: this parameter assesses the extent of 
muscle contracture. It was tested by placing the 
thumb and the index fingers between patient's upper 
and lower teeth and applying a firm force to passively 
increase the incisal distance. It was recorded as 
“positive” when greater than 2 mm, due to the 
physiological stretching of the ligaments (joint play). 
d) Opening derangement (OD): in a healthy 
masticatory system, the movement of the jaw in the 
opening path is straight. The alterations in the course 
of opening have been classified as: 
i) deviation: any shift of the jaw from the midline 
during opening that disappears continuing the 
opening (return of the jaw to the midline); 
ii) deflection: any shift of the mandibular midline 
that increases continuing opening and does not 
disappear in maximum opening (jaw doesn’t return to 
the midline) [46]. 
Myofacial pain (MP) 
While healthy muscles do not elicit pain when 
palpated, ache may be elicited by compression of 
inflamed or contracted muscles. These data were 
collected as categorical (presence/absence of pain) 
through digital palpation of the masticatory muscles, 
performed mainly by the thumb and the index finger, 
applying a soft but firm pressure to the muscle. 
The following masticatory muscles were 
palpated bilaterally: anterior, medial, and posterior 
temporalis muscle, superficial and deep masseter 
muscle, medial pterygoid muscle, lateral pterygoid 
muscle with its superior and inferior head, digastric 
(anterior and posterior belly) muscle, mylohyoid and 
sternocleidomastoid muscles. 
Patients were also asked to express the intensity 
of perceived pain for each muscle, using the VAS scale 
(from 0 to 3) [47]. 
Statistical Analysis 
Categorical data were expressed as number and 
percentage and comparisons between ERA and 
control patients were performed using chi-squared 
(χ2) test and, if not applicable, Fisher or Mid-p exact 
tests. Quantitative data were presented as mean and 
Standard Deviation (SD) and the comparisons 
between two groups were valued by means of 
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Student’s T test for unpaired samples. In all 
comparisons, a p value ≤0.05 was considered 
statistically significant. Statistical analyses were 
performed by using Epi Info 3.5 for categorical data 
and GraphPad Prism 6.0 for quantitative ones. 
Results 
1. Characteristic of ERA Patients and Controls 
Patients’ age ranged between 8 and 86 years, 
78.8% were female and 21.2% were male in both 
groups. The two groups, matched for age and sex, 
resulted quite similar for sociodemographic aspects. 
However, retirees were prominent in the study group, 
while housewives were more numerous in the control 
one (Table 1). 
 
Table 1. Sociodemographic characteristics of ERA patients and 
controls. 
Sociodemographic 
Characteristics 
ERA Controls Test p Value 
Age, mean ± SD  55,96 ± 19,01  52,73 ± 15,82   
Sex, n (%) 
 male  11 (21,2%)  11 (21,2%)   
 female  41 (78,8 %)  41 (78,8 %) 
Educational degree, n (%) 
 primary 12 (24,5%) 12 (24,0%)  χ2= 1,731  0,630 
 secondary 13 (26,5%)  9 (18,0%) 
 high 16 (32,7%) 22 (44,0%) 
 academic  8 (16,3%)  7 (14,0%) 
Occupation, n (%) 
 housewife  10 (19,2%)   20 (38,5%)  χ2 =26,746  0,0002 
 office worker  10 (19,2%)  2 (3,8%) 
 retired  14 (26,9%)  5 (9,6%) 
 self employed  10 (19,2%)  3 (5,8%) 
 public employed  4 (7,7%)  19 (36,5%) 
 not employed  4 (7,7%)  3 (5,8%) 
Marital status, n (%) 
 married  33 (63,5%)  34 (65,4%)  χ2 = 3,348  0,341 
 widower  4 (7,7%)  8 (15,4%) 
 single  11 (21,2%)  9 (17,3%) 
 divorced  4 (7,7%)  1 (1,9%) 
 
Comorbidities of ERA patients and controls are 
reported in Table 2. 
 
Table 2. Clinical characteristics of ERA patients and controls. 
Comorbidities ERA Controls Test p Value 
Cardiopathy 7 (13,5%) 5 (9,6%) Χ2= 0,377 0,539 
Diabetes mellitus 4 (7,7%) 3 (5,8%) Fisher’s exact 
test 
0,500 
Hypertension 26 (50,0%) 13 (25%) X2= 6,933 0,008* 
Hypovitaminosis D 38 (73,1%) 1 (1,9%) X2= 56,164 < 0,001* 
Osteoporosis 17 (32,7%) 1 (1,9%) X2= 17,199 < 0,001* 
Esophageal disease 11 (21,2%) 0 (0,0%) X2= 12,301 < 0,001* 
Gastroenteric disease 6 (11,5%) 1 (1,9%) Fisher’s exact 
test 
0,056 
Lung disease 8 (15,4%) 0 (0,0%) Fisher’s exact 
test 
0,003* 
Kidney disease 7 (13,5%) 1 (1,9%) Fisher’s exact 
test 
0,029* 
Thyroid disease 19 (36,5%)  7 (13,5%) X2= 7,385 0,006* 
Neurological disease 2 (3,8%) 1 (1,9%) Fisher’s exact 
test 
0,500 
Raynaud disease 0 (0,00%) 0 (0,0%) - - 
Disease Activity 
The CDAI score indicates on average a low 
disease activity (from> 2.8 to 10.0); also the score of 
SDAI indicates a low disease activity (from> 3.3 to 
≤11.0). DAS 28 indicates that on average the disease is 
in clinical remission (<2.6) (Table 3). 
 
Table 3. Activity indexes of ERA. 
Activity indexes of ERA Mean ± SD 
CDAI (range 0- 76,0) 2,953±5,892 
SDAI (range 0- 86,0) 3,572±6,028 
DAS28 (range 0- 9,4) 2,469±1,764 
 
Pharmacological Therapy 
Approximately 42% of patients with ERA take 
corticosteroid medications, almost 80% sDMARDs 
(synthetic disease-modifying antirheumatic drugs), 
and about 34% biologic DMARDs (bDMARDs). Many 
of them take combined therapies (Table 4). 
 
Table 4. Pharmacological therapy in ERA patients. 
Pharmacological therapy Patients 
Corticosteroids 22 (42,3%) 
sDMARDs 41 (78,8%) 
bDMARDs 18 (34,6%) 
 
Regarding the beginning of treatment, 90.4% of 
patients started drug therapy within 4 months after 
diagnosis of ERA, 3.8% between 4 and 8 months after 
diagnosis, 5.8% after 8 months. 
2. Oral Characteristics 
The oral characteristics analyzed were the 
presence/absence of partial or total edentulism, the 
presence/absence of prostheses (mobile, fixed or 
both), and any previous or present orthodontic 
treatment. Among the three parameters, only the 
presence of prostheses was significantly prominent in 
ERA patients (50.0%). These data were analyzed using 
the χ2 test (Table 5). 
 
Table 5. Oral characteristics of ERA patients and controls. 
Oral characteristics ERA Controls Test p Value 
Partial or total edentulism 28 (53,8%) 21 (40,4%) X2= 1,891 0,169 
Presence of prostheses (mobile, 
fixed, partial or total) 
26 (50,0%) 10 (19,2%) X2= 10,875 < 0,001* 
Present or previous orthodontic 
treatments 
 8 (15,4%)  6 (11,5%) X2= 0,330 0,565 
 
3. Oral Symptoms  
Statistically significant differences were not 
found in the study group and in the control one 
(p>0,05). Presence of xerostomia, dysgeusia and 
stomatodynia results qualitatively overlapping in the 
two groups. These data were analyzed using the χ2 
test and the Fisher exact test (Table 6). 
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Table 6. Oral symptoms of ERA patients and controls. 
Oral symptoms ERA Controls Test p Value 
Xerostomia 14 (26,9%) 9 (17,3%) X2= 1,396 0,237 
Dysgeusia  1 (1,9%) 3 (5,8%) Fisher’s exact test 0,308 
Stomadodynia  1 (1,9%) 2 (3,8%) Fisher’s exact test 0,500 
 
4. TMD  
4.1 Symptoms 
The valuation of TMDs showed that 67,3% of the 
patients with ERA and 90,4% of the controls 
complained one or more symptoms. Statistically 
significant differences were found for all subjective 
complaints, except for masticatory muscle pain 
(p=0,237) and for temporal headache (p=0,315). These 
data were analyzed using the χ2 test (Table 7). 
 
Table 7. TMD symptoms in ERA patients and controls. 
TMD symptoms ERA Controls Χ2 
Test 
p 
Value 
Masticatory muscle pain 9 (17,3%) 14 (26,9%)  1,395 0,237 
Soreness or muscle pain of neck and 
shoulders 
22 (42,3%) 37 (71,2%)  8,814 0,002* 
Muscle pain during the function 11 (21,2%) 25 (48,1%)  8,326 0,003* 
Arthralgia tmj 13 (25,0%) 28 (53,8%)  9,059 0,002* 
Difficulty opening mouth 6 (11,5%) 23 (44,2%) 13,818 <0,001* 
Temporal headache 18 (34,6%) 23 (44,2%)  1,006 0,315 
Tinnitus 13 (25,0%) 29 (55,8%) 10,224 0,001* 
TOTAL 35 (67,3%) 47 (90,4% )  8,301 0,004* 
 
4.2 Myofacial pain 
For almost all muscles examined through 
palpation, pain reported was significantly higher in 
the control group than in the study one (p≤0,05). No 
significant differences between the two groups were 
found for medial temporal muscles, 
sternocleidomastoid muscles (clavicular head) and for 
superficial and deep masseter muscles. These data 
were analyzed using the χ2 test (Table 8). 
 
Table 8. Myofascial pain in ERA patients and controls. 
Pain on muscle palpation ERA Controls Χ2 Test p Value 
Anterior temporalis muscle  7 (13,5%) 27 (51,9%) 17,479 < 0,001* 
Medial temporalis muscle  5 (9,6%)  7 (13,5%) 0,376 0,539 
Posterior temporalis muscle  4 (7,7%) 14 (26,9%) 6,718 0,009* 
Sternocleidomastoid 
muscles—sternal head 
11 (21,2%) 24 (46,2%) 7,277 0,006* 
Sternocleidomastoid 
muscles—clavicular head 
11 (21,2%) 15 (28,8%) 0,820 0,365 
Digastric muscle—anterior belly  2 (3,8%) 14 (26,9%)  10,636 0,001* 
Digastric muscle—posterior belly  5 (9,6%) 18 (34,6%) 9,434 0,002* 
Superficial masseter muscles 22 (42,3%) 30 (57,7%) 2,461 0,117 
Deep masseter muscles 22 (42,3%) 25 (48,1%) 0,349 0,554 
Medial pterygoid muscles 11 (21,2%) 30 (57,7%) 14,535 < 0,001* 
Lateral pterygoid muscles 27 (51,9%) 39 (75,0%) 5,971 0,014* 
Mylohyoid muscles  6 (11,5%) 25 (48,1%) 16,59 < 0,001* 
TOTAL 30 (57,7%) 42 (80,8%) 6,5 0,01* 
 
5. TMJ Signs 
5.1. TMJ sounds: overall, there was a light 
reduction in joint noises in the group of ERA patients 
compared to the control one, but no statistically 
significant difference was detected. These data were 
analyzed using the χ2 test (Table 9). 
 
Table 9. TMJ noises in ERA patients and controls. 
TMJ noises ERA Controls X2 Test p Value 
Clicking during the 
opening 
 7 (13,5%) 12 (23,1%) 1,609 0,204 
Reciprocal clicking  6 (11,5%)  8 (15,4%) 0,330 0,565 
Snapping  9 (17,3%) 14 (26,9%) 1,396 0,237 
Crepitation 12 (23,1%)  8 (15,4%) 0,990 0,319 
TOTAL 19 (36,5%) 29 (55,8%) 3,869 0,049* 
 
5.2 Bruxism: the prevalence of clenching showed 
a statistically significant decrease in ERA patients 
compared with controls. In detail, dental wear facets 
were more present in the control group in a 
statistically significant way, while irregular lingual 
edges and buccal occlusal line showed no significant 
differences among the two groups. These data were 
analyzed using the χ2 test (Table 10). 
 
Table 10. Bruxism and its oral signs in ERA patients and controls. 
Bruxism and oral 
signs 
ERA Controls X2 Test p Value 
Teeth clenching  9 (17,3%) 27 (51,9%) 13,765 < 0,001* 
Bruxism (Teeth 
grinding) 
 9 (17,3%) 15 (28,8%)  1,950 0,163 
Wear facets 16 (30,8%) 30 (57,7%)  7,640 0,006* 
Irregular lingual edges 20 (38,5%) 20 (38,5%)  0,00 1,00 
Buccal occlusal line 13 (25,0%) 12 (23,0%)  0,052 0,818 
 
5.3. Mandibular kinematics (MK) and restriction 
of movements (RM): values of active mouth opening, 
right lateral excursion and protrusion (calculated by 
T-student test) showed no statistically significant 
difference between ERA and control patients. Left 
lateral excursion, on the contrary, resulted restricted 
in statistically significant way in ERA patients 
(p=0,017) (Fig. 1). Finally, the end-feel, considered 
positive for values > 2 mm, was increased in both 
groups, but more significantly in the group of sick 
subjects (Fig. 2). This finding shows objectively the 
presence of a muscle contracture in patients with ERA 
(p=0,002) (Table 11). 
 
Table 11. Mean values of mandibular kinematics in ERA patients 
and controls. 
Mean values of mandibular 
kinematics (Mean in mm ± SD) 
ERA Controls p Value 
Maximal active mouth opening ± 
SD 
42,78± 6,03 42,83±5,60 0,970 
Right lateral excursion ± SD 6,37±2,98  7,37±2,43 0,07 
Left lateral excursion ± SD 6,35±3,29  7,79±2,56 0,017* 
Protrusion ± SD 4,33±3,25  5,39±2,58 0,076 
Endfeel ± SD 3,95±1,28  2,96±1,10 0,002* 
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Figure 1. A, B. Mean values ± SD of ERA and control group. Laterotrusion 
side evaluation reveals a statistically significant reduction of left lateral 
excursion. 
 
5.4. Opening derangement (OD): the presence of 
alterations in the mouth opening pathway analyzed 
by χ2 test (p=0,007) for deviation and by Mid-p exact 
test (p=0,037) for deflection, resulted significantly 
reduced in ERA patients (Table 12). 
 
Table 12. Opening derangement in ERA patients and controls. 
Opening 
Derangement 
ERA Controls Test p Value 
Deviation 11 (21,2%) 24 (46,2%) χ2= 7,278 0,007* 
Deflection  3 ( 5,8%)  9 (17,3%) Mid-p exact test 0,037* 
 
6. Oral signs 
The presence of ulcers was significantly reduced 
in subjects with ERA, while the presence of 
erythematous and hyperkeratotic areas, candidiasis, 
angular cheilitis, erythema, fissured tongue and 
petechiae was substantially overlapping in the two 
groups. These data were analyzed using the χ2 test or 
Fisher's exact test (Table 13). 
Table 13. Oral signs for ERA patients and controls. 
Oral signs ERA Controls Test p Value 
Oral ulcerations (aphthae) 3 (5,8%) 10 (19,2%) χ2= 4,307 0,038* 
Erythema 0 (0,00%)  1 ( 1,9%) Fisher’s exact test 0,500 
Candidiasis 0 (0,00%)  1 ( 1,9%) Fisher’s exact test 0,500 
Angular cheilitis 4 (7,7%)  4 ( 7,7%) Fisher’s exact test 0,642 
     
Hyperkeratotic or 
erythematous areas of the 
mucosa 
0 (0,00%)  2 (3,8%) Fisher’s exact test 0,247 
Fissured tongue 
Petechiae 
6 (11,5%) 
0 (0,0%) 
 6 (11,5%) 
 1 ( 1,9%) 
Fisher’s exact test 
Fisher’s exact test 
0,619 
0,500 
 
 
Figure 2. A, B, C. Mean values ± SD of ERA and control group. Movement 
width evaluation shows no statistically significant differences, except for endfeel. 
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7. Salivary flow 
Regarding the extent of salivary flow (Fig. 3), 
measured in 5 minutes, there was a statistically 
significant reduction in the ill subjects compared to 
controls (Table 14). 
 
 
Figure 3. Mean values ± SD of ERA and control group. ERA patients show a 
reduced salivary flow. 
 
Table 14. Mean values of salivary flow in ERA patients and 
controls. 
Mean values of salivary flow 
(Mean in ml ± SD) 
ERA Controls p Value 
Salivary flow ± SD 0,058±0,235 2,962±1,102 <0,0001* 
 
Discussion 
Rheumatoid Arthritis (RA) is an autoimmune 
polyarthritis characterized by the chronic 
inflammation of synovial joints of the hands, wrists, 
elbows, shoulders, hips, knees, feet and, less 
frequently, temporomandibular ones. It is a 
potentially fatal disease, involving several 
extra-articular organs, the damage of which is as 
minor as the diagnosis is earlier. RA related oral 
implications can be hyposalivation, difficulty in 
swallowing and phoning, feeling of burning mouth, 
increased thirst, loss of taste or unpleasant taste and 
smell, dental sensitivity. 
Temporomandibular disorders (TMD) represent 
a heterogeneous group of inflammatory or 
degenerative diseases of the stomatognatic system, 
with algic and/or dysfunctional clinical features, 
involving temporomandibular joint (TMJ) and related 
masticatory muscles.  
Previous studies in literature investigated the 
relationship between TMDs and RA [25, 48, 49, 50, 51], 
but none of them used a cohort of patients with an 
Early diagnosed RA. In addition, the present study 
focused not only the prevalence of TMD symptoms 
and signs, but highlighted also the oral implications in 
ERA patients compared with controls. Most of 
findings of this investigation did not reveal 
statistically significant differences between ERA 
patients with controls. Myofacial pain (MP) evoked by 
palpation was less frequent and severe than in the 
control group, while a weak TMJ kinematic 
impairment, a paucisymptomatic muscle contracture 
(positive endfeel) and a statistically significant 
reduction of salivary flow were more represented in 
the study group. 
In detail, about education from primary school 
to the academic degree, ERA group had a similar 
prevalence of controls. Retirees and self-employed 
were much more represented in ERA patients (Table 
1). Local and systemic conditions due to the 
syndrome, from the most common findings such as 
pain, joint stiffness, asthenia, weakness and fatigue, to 
the awareness of an increased risk of comorbidities 
and death, can worsen quality of life and 
psychological status of ERA patients, thus limiting 
their activities and their participation in society.  
However, these psychological and physical 
impairments seem to be more attenuated in ERA 
patients if compared with ones affected by juvenile 
idiopathic arthritis (JIA). This kind of arthritis can 
lead to a severe impairment of patients' quality of life, 
with troubles in daily functions, such as dressing, 
grooming, walking, and writing. Emotional aspects, 
such as self non-acceptance, can damage JIA patients’ 
social life. They showed also an oral health-related 
quality of life worse than HC, with limitations in 
eating, smiling, performing oral hygiene [51]. 
Irrespective of these limitations, Mühlberg 
detected only a lower prevalence of periodontitis and 
no increase in the number of missing teeth in the RA 
group compared to the CG. These finding about the 
dental status corresponds with the results of the 
current study. The presence/absence of partial or 
total edentulism (Table 5) between ERA patients and 
CG shows no statistically significant difference 
(p=0,169) [52]. 
Current or previous orthodontic treatments were 
present in a small percentage both in ERA sample and 
in CG, respectively 15.4% and 11.5%. The application 
of orthodontic forces determines a biological 
response, resulting in a remodeling of the alveolar 
bone and the periodontal ligament, whose 
proprioceptors give information on movement and 
position of the stomatognathic system [53]. The early 
stage of orthodontic treatment consists of an acute 
inflammatory response, characterized by a loss of the 
normal tissue architecture, a change of collagen I, 
collagen IV and fibronectine. The amount of cytokines 
increases during tooth movement, with a release of 
inflammatory mediators, such as prostaglandin E 
(PGE). Consequently, undesired effects of the 
treatment can be root resorption and loss of alveolar 
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bone. In ERA group, as well as in control group, 
orthodontic treatment gave no above mentioned side 
effect, probably thanks to a promptly started drug 
therapy [54].  
The current study showed an increased 
prevalence of hypertension, thyroid, lung, kidney and 
esophageal diseases in ERA patients (Table 2), with 
findings similar to those reported by Chandrashekara 
et coworkers [55]. An interesting finding in patients’ 
history is osteoporosis, affecting 17 (32.7%) ERA 
patients versus 1 (1.9%) of control group, due to a 
chronic bone inflammation and to a prolonged intake 
of corticosteroids (Table 4). Consequently, a higher 
rate of ERA patients takes bisphosphonates, a 
long-term antiresorptive therapy, which could cause, 
as a side effect, a medication-related osteonecrosis of 
the jaws (MRONJ) after oral surgery. Therefore, 
dentists should consider ERA patients as a potential 
risk category. About hypovitaminosis D, the higher 
prevalence in ERA patients (n=38, 73.1%) versus 
control group (n=1, 1.9%) could be explained in a 
constant monitoring of this parameter in ERA 
patients. The lack of a routinary haematological 
analysis in the control group could lead in fact to 
underestimated data. All the patients started drug 
therapy within 12 months after diagnosis of ERA: 
90.4% within 4 months, 3.8% between 4 and 8 months, 
5.8% after 8 months. The drugs used for the treatment 
were: corticosteroids (42.3%), sDMARDs (78.8%) and 
bDMARDs (34.6%). Many patients took combined 
therapies (Table 4).  
About muscular and TMJ symptoms, they 
included neck and shoulders pain or soreness, pain 
during movement of masticatory muscles, arthralgia 
of TMJ, feeling of locked jaws during opening mouth, 
and tinnitus. All these were proved to be more 
recurring findings in the control group than in the 
study one (Table 7). 
Painful symptoms related to muscle palpation 
were all much more present in the control group. In 
detail, statistically significant differences were 
detected in anterior and posterior temporalis muscles, 
sternocleidomastoid muscle-sternal head, digastric 
muscle (anterior and posterior bellies), medial and 
lateral pterygoid muscles, and mylohyoid muscle 
(Table 8). However, positive end-feel values (Table 11) 
showed objectively a higher presence of a 
paucisymptomatic muscle contracture in patients 
with ERA compared with the control ones (p=0,002).  
These phenomena are probably linked to drug 
therapy: corticosteroids cause the down-regulation of 
proinflammatory chemokines, adhesion molecules 
and cytokines such as tumor necrosis factor (TNF), 
interleukin-1(IL-1), IL-6, intercellular cell adhesion 
molecules (ICAM-1) and vascular cell adhesion 
molecule (VCAM-1). They also function as selective 
inhibitors of cyclooxygenase 2 (COX-2) by increasing 
the synthesis of lipocortin-1, a 37-kDa protein that has 
an inhibitory effect on phospholipase A2 (PLA2), 
therefore down regulates the production of 
arachidonic acid metabolites including 
prostaglandins and leukotrienes [56], which are 
responsible for inflammation and damage both to the 
joints and to other sites in the body.  
Also conventional DMARDs and biological 
drugs act at the level of the immune system [57], 
impairing the binding of pro-inflammatory cytokines 
to their receptors, that play an important role in the 
pathogenesis of RA [58], thus leading to a rapid 
improvement in joint pain and swelling. 
It is clear, therefore, that if patients affected by 
ERA take these drugs stably, pain and inflammation 
will be inhibited not only in the joints, but also in 
other parts of the body, including for example muscle 
tissue. In the present work, the study sample 
consisted of subjects with Early Rheumatoid Arthritis, 
i.e. patients who had received an early diagnosis of 
disease within 12 months from the onset of 
symptoms, and therefore had promptly started a 
correct drug therapy. Moreover, they had, on average, 
a low disease activity or clinical remission at the time 
of observation (Table 3). Therefore, minimal damages 
in joints and muscles (as well as in other districts) 
were expected. Muscular pain, in fact, was less 
present in ERA patients than in controls, even if the 
first ones had a major muscular contracture. Also joint 
damages and joint signs were less present in ERA 
patients than in controls: at the clinical examination, 
they showed a statistically significant reduction of the 
presence of TMJ noises (p=0,049), which generally 
indicate morphological alterations of the bony heads 
or joint damage (Table 9). 
Muscular contracture, as well as the positive 
end-feel, was also objectified by a limitation in the 
mandibular kinematics, which, although only in the 
left laterality showed a statistically significant 
reduction compared to the control group (p=0,017), 
was evidenced also in the movements of right 
laterality and protrusion (Table 11). 
The use of these pharmacological therapies 
could also explain the statistically significant 
reduction in patients with ERA compared to controls, 
of changes in the mouth opening pathway: deviation 
(p=0,007) and deflection (p=0,037). Often, in fact, they 
are related to the presence of morphological 
alterations in the condyle, such as osteophytes or bone 
beaks, which in these patients are slowed down, if not 
blocked, by the aforementioned precocious therapies 
(Table 12). 
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With regard to the statistical significance of the 
reduction of dental clenching in patients with ERA 
compared to controls (p<0,001), it can be explained by 
a condition of muscle weakness that develops 
frequently in this pathology, traditionally thought to 
be caused by a loss of muscle mass and an impaired 
intrinsic contractility also present in patients with RA 
[59], but also linked to nitrosative modifications of the 
RyR1 protein complex and actin, which are driven by 
increased nNOS associated with RyR1 and 
progressively increasing Ca2+ activation [60]. 
As a result, even dental wear facets were 
significantly less present in cases than in controls 
(p=0,006) (Table 10). 
Taking into account oral signs, only the presence 
of oral ulcerations (aphthae) was significantly 
reduced in subjects with ERA compared to controls 
(p=0,038) (Table 13). 
About oral symptoms, statistically significant 
differences were not found between the study group 
and the control one (p>0,05) (Table 6). Also 
xerostomia was overlapping in the two groups, 
although ERA patients presented a considerably 
reduced salivary flow compared to the controls 
(p<0,0001) (Table 14). This result is probably due to 
the drug therapies, which included many xerogenic 
medications. This outcome is in agreement with 
Torres’ results [61], who showed that subjects with 
RA presented reduced resting salivary flow when 
compared to healthy controls.  
Conclusion 
The aim of this observational study was to 
investigate the prevalence of TMD symptoms and 
signs as well as oral implications in patients with 
ERA, that is a RA diagnosed within 12 months, 
compared with people not affected by this disease. 
Myofacial pain (MP) evoked by palpation was more 
frequent and severe in the control group than in the 
study one, this result being highly significant. 
The data collected show also a weak TMJ 
kinematic impairment, a paucisymptomatic muscle 
contracture (positive endfeel) and a statistically 
significant reduction of salivary flow in ERA patients 
when compared to the control group.  
Therefore, an interdisciplinary collaboration 
between the stomatologist and the rheumatologist is 
desirable, for a more complete clinical overview and 
for a more efficient treatment of this disease. 
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